Venous Leg Ulcer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Venous Leg Ulcer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A8117
Year End sale Buy Now

 Market Overview:

The 7 major venous leg ulcer markets reached a value of US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.3% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 2.1 Billion
Market Forecast in 2034
US$ 3.3 Billion
Market Growth Rate (2024-2034)
4.3%


The venous leg ulcer market has been comprehensively analyzed in IMARC's new report titled "Venous Leg Ulcer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Venous leg ulcer refers to an open wound that occurs on the lower leg, typically around the ankle or calf region, as a result of chronic venous insufficiency. These ulcers are usually characterized by shallow and irregular edges, which are surrounded by areas of discolored, reddish-brown skin. Individuals suffering from this disease may experience pain, aching, or a feeling of heaviness in the affected leg. Numerous other indications include swelling, itching, dryness, a yellowish or clear fluid that oozes from the wound, hardened skin, slow healing, etc. The diagnosis of a venous leg ulcer generally involves a comprehensive medical history evaluation, a clinical symptoms review, and a physical examination. In some cases, blood tests may be utilized to assess overall health or evaluate any underlying systemic diseases that may contribute to poor wound healing. The healthcare provider may also perform a Doppler ultrasound, which uses sound waves to examine blood flow in the veins and determine if the venous system is functioning properly. Furthermore, a biopsy is typically necessary to confirm the diagnosis of the ailment.

Venous Leg Ulcer Market

The increasing cases of weakened or damaged valves of the leg veins due to which blood can pool and accumulate in the veins, thereby leading to high pressure, are primarily driving the venous leg ulcer market. In addition to this, the rising incidences of various associated risk factors, such as a history of deep vein thrombosis, obesity, older age, smoking, diabetes, a sedentary lifestyle, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of compression pump therapy, which utilizes a device that intermittently applies external pressure to the legs, promoting venous return and reducing edema, is further bolstering the market growth. Apart from this, the escalating demand for topical medications, including antimicrobial agents and analgesics, owing to their numerous benefits, like minimized trauma during dressing changes and lowered risk of infections, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of negative pressure wound therapy that involves the application of a vacuum dressing over the wound to stimulate blood flow and promote granulation tissue formation is expected to drive the venous leg ulcer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the venous leg ulcer market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for venous leg ulcer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the venous leg ulcer market in any manner.

Recent Developments

  • In March 2024, SolasCure Ltd. revealed the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal. The Phase IIa data confirm the efficacy and safety of Aurase Wound Gel in humans for wound healing via debridement and wound bed preparation.
  • In February 2024, MediWound Ltd. announced the results of head-to-head comparison analyses of EscharEx, a bromelain-based gel for chronic wounds, and collagenase SANTYL ointment, an FDA-approved treatment for chronic cutaneous ulcers, within the ChronEx phase II randomized controlled study. The findings indicate that EscharEx is superior to SANTYL in wound debridement, stimulation of granulation tissue, and duration to wound closure in patients with chronic venous leg ulcers.
  • In April 2023, MTF Biologics launched AlloPatch Pliable Meshed to its range of superior, innovative, and effective wound care products. AlloPatch Pliable Meshed is an acellular human reticular dermal allograft intended to help repair difficult-to-treat lesions such as venous leg ulcers.
  • In March 2023, Sky Medical Technology disclosed the publication of its landmark multicenter randomized self-controlled trial, which compared the standard of care (SoC) with and without the company's Geko device in patients with difficult-to-heal venous leg ulcers. This research, in which patients served as their controls, found that patients treated with the Geko neuromuscular electrostimulation device healed more quickly than those treated with SoC alone.


Key Highlights:

  • Venous leg ulcers are a widespread, chronic, recurring ailment with an estimated frequency of 0.1% to 0.3% in the United Kingdom.
  • Venous leg ulcers are typically caused by venous reflux or blockage, but 20% of those with venous leg ulcers have arterial disease, either with or without venous problems.
  • Around 75% to 80% of total lower-extremity wounds are venous leg ulcers.
  • Over the age of 65, the prevalence of venous leg ulcers increased to 4%.
  • On average, 33-60% of venous leg ulcers persist for more than six weeks and are, therefore, known as chronic venous leg ulcers.
  • Every year, nearly 2 million people with venous leg ulcers are eligible for debridement in the United States alone.


Drugs:

EscharEx, a bioactive treatment for the debridement of chronic and several other difficult-to-heal wounds, is a product candidate in advanced development. It is designed to be applied topically to the wound bed over numerous 24-hour periods until the necrotic tissue is eliminated and the wound is debrided. EscharEx's mechanism of action is mediated by proteolytic enzymes, which break and eliminate necrotic tissue, preparing the wound bed for healing.

S42909 is a small molecule drug indicated in the treatment of venous lower limb ulcers. It exerts a potent NADPH oxidase inhibitor activity, along with vascular anti-inflammatory properties.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the venous leg ulcer market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the venous leg ulcer market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current venous leg ulcer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance    
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
EscharEx MediWound
S42909 Ilkos Therapeutic Inc.


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the venous leg ulcer market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the venous leg ulcer market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the venous leg ulcer market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of venous leg ulcer across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of venous leg ulcer by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of venous leg ulcer by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with venous leg ulcer across the seven major markets?
  • What is the size of the venous leg ulcer patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of venous leg ulcer?
  • What will be the growth rate of patients across the seven major markets?
     

Venous Leg Ulcer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for venous leg ulcer drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the venous leg ulcer market?
  • What are the key regulatory events related to the venous leg ulcer market?
  • What is the structure of clinical trial landscape by status related to the venous leg ulcer market?
  • What is the structure of clinical trial landscape by phase related to the venous leg ulcer market?
  • What is the structure of clinical trial landscape by route of administration related to the venous leg ulcer market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Venous Leg Ulcer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase Options Year End sale




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More
Gulf Excellent Group

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Read More
FS Corporation Inc.

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

Read More
Egyptian Industrial Investment Group

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

Read More
Vishnu Chemicals

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

Read More
MOUNT EVEREST BREWERIES LIMITED

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

Read More
Borges Branded Foods

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

Read More
Godrej Consumer Products Limited

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

Read More
ADC Therapeutics

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

Read More
Ivanti

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

Read More
Asiatic Electrical & Switchgear P. Ltd.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Read More
Denka Co., Ltd.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.

Read More